cyclosporine has been researched along with Cytokine Release Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Romero-Bueno, FI; Sanchez-Pernaute, O; Selva-O'Callaghan, A | 1 |
| Clerici, M; Daniele, T; Fenizia, C; Galbiati, S; Tacchetti, C; Vago, R; Vanetti, C | 1 |
| Chiba, S; Hasegawa, Y; Kato, T; Kurita, N; Kusakabe, M; Nishikii, H; Obara, N; Sakamoto, T; Sakata-Yanagimoto, M; Yokoyama, Y | 1 |
1 trial(s) available for cyclosporine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Cyclosporine; Cytokine Release Syndrome; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Transplantation, Haploidentical; Young Adult | 2021 |
2 other study(ies) available for cyclosporine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.
Topics: Antibodies, Monoclonal, Humanized; COVID-19 Drug Treatment; Cyclosporine; Cytokine Release Syndrome; Humans; Immunosuppressive Agents; SARS-CoV-2 | 2021 |
Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Topics: Anti-Inflammatory Agents; Antiviral Agents; COVID-19; Cyclosporine; Cytokine Release Syndrome; Cytokines; Humans; Lung; SARS-CoV-2; Virus Release | 2022 |